Cambridge, Massachusetts-based Agios Pharmaceuticals, Inc. has reportedly closed its initial public offering (IPO) of more than 6.7 million shares of common stock, raising $106 million at an IPO price of $18 per share. The company also intends to offer an additional 883,000 shares for overallotments, according to a news source. The company has several drug candidates that target cellular metabolism to treat cancer and rare genetic disorders known as inborn errors of metabolism or IEMs. According to a company statement, “We intend to apply our deep understanding of metabolism, coupled with our ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and IEMs are treated.” See Agios Pharmaceuticals News Release, July 29, 2013.